Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
A8K979
UPID:
ERI2_HUMAN
Alternative names:
Exonuclease domain-containing protein 1
Alternative UPACC:
A8K979; Q6ZSJ2; Q96FR9; Q9P224; Q9Y6V3
Background:
ERI1 exoribonuclease 2, also known as Exonuclease domain-containing protein 1, plays a crucial role in RNA metabolism and the RNA interference pathway. Its specific functions in cellular processes and molecular mechanisms are subjects of ongoing research, highlighting its importance in understanding RNA-related functions.
Therapeutic significance:
Understanding the role of ERI1 exoribonuclease 2 could open doors to potential therapeutic strategies. Its involvement in RNA processing suggests it may be a key player in diseases where RNA dysregulation occurs, offering a promising target for drug discovery.